发现口服活性的硫基基[3,2-d]胺衍生物作为GPR119激动剂
Heecheol Kim1, Minjung Kim2, Kyujin Oh2
1Hanmi Research Center, Hanmi Pharm. Co., Ltd., Hwaseong-si, 18469, Republic of Korea; College of Pharmacy, Chung-Ang University, Seoul, 06974, Republic of Korea; Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, 06974, Republic of Korea.
European journal of medicinal chemistry
|June 25, 2023
概括
新型[3,2-d]胺衍生物被确定为GPR119激动剂,用于治疗II型糖尿病. 化合物43在动物模型中表现出强烈的活性,改善了体内葡萄糖耐受性,并降低了血糖水平.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
背景情况:
- G蛋白结合受体119 (GPR119) 是II型糖尿病的一个有前途的治疗点.
- 开发GPR119的新型激动剂对于代谢疾病治疗至关重要.
研究的目的:
- 发现和表征新[3,2-d]胺衍生物作为强大的GPR119激动剂.
- 评估化合物的体内疗效和药理动力学特性.
主要方法:
- 生物异构体替代策略被用来设计新的化学实体.
- 基于细胞的测试被用来评估GPR119的激动活性.
- 在动物模型中进行了药理动力学分析和口服葡萄糖耐受性测试 (OGTT).
主要成果:
- 新型硫基[3,2-d]胺衍生物被合成并被确定为强大的GPR119激动剂.
- 衍生物43在动物中表现出有利的药物动力学特征.
- 化合物43在OGTT期间显著改善了小鼠和老鼠的葡萄糖耐受性,并降低了血糖水平.
结论:
- 提[3,2-d]胺衍生物代表了一类有前途的GPR119激动剂.
- 化合物43显示出治疗II型糖尿病的治疗潜力,因为它的疗效和药理动力学特性.
相关概念视频
Oral Hypoglycemic Agents: Sulfonylureas
247
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
247
Glucagon-like Receptor Agonists
366
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
366
Oral Hypoglycemic Agents: Glinides
189
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
189
G Protein-coupled Receptors
12.3K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
12.3K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
316
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
316


